Document is current

Article History

Received: 2 August 2021

Accepted: 16 February 2022

First Online: 29 March 2022

Competing interests

: S.B. declares no conflicts of interest. S.K. reports consulting fees from F. Hoffmann-La Roche Ltd., Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Somatex, MSD, Pfizer, Puma Biotechnology, PFM Medical, Lilly and SonoScape; leadership roles with Westdeutsche Studiengruppe and Arbeitsgemeinschaft Gynäkologische Onkologie; research grant/funding from Somatex and Roche; travel expenses from F. Hoffmann-La Roche Ltd., Daiichi-Sankyo and SonoScape; and partial non-profit ownership of Westdeutsche Studiengruppe. N.H. reports fees for lectures and/or consulting from AstraZeneca, Daiichi Sankyo, MSD, Lilly, Novartis, Pfizer, Roche, and Seattle Genetics; partial non-profit ownership of West German Study Group (WSG). P.S. reports advisory/consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, and Roche; grant/funding to the institution from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex and Roche; and a spouse who is an employee of Roche. J.C. reports advisory role/consultancy for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, and Boehringer Ingelheim; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, and Daiichi Sankyo; research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London; stock, patents and intellectual property from MedSIR; and travel, accommodation, expenses from Roche, Novartis, Eisai, Pfizer, and Daiichi Sankyo. C.S. reports travel expenses from Teva. O.C. reports travel expenses from Pfizer. H.H. reports travel expenses from Teva and Pfizer. B.A. reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees from AstraZeneca, personal fees and non-financial support from Tesaro/GSK, personal fees from Clovis, personal fees from Celgene, non-financial support from PharmaMar, personal fees and non-financial support from MSD, personal fees from Novartis, outside the submitted work. M.H.D. reports personal fees from Boehringer Ingelheim, Merck, Novartis, EUSA Pharma, AbbVie, Janssen, Biogen, Menarini and Norgine (outside the submitted work). S.S. reports professional fees from Sanofi, Abbvie, Bayer, Cantargia, Celgene, Ferring, Nestle, Servier, Tiburio, and Zentiva on unrelated freelance projects. E.T. has declared no conflicts of interest. I.T. has declared no conflicts of interest. D.G. has declared no conflicts of interest. O.G. reports minority non-profit ownership of WSG Study Group; honoraria from Genomic Health, Roche, Celgene, Pfizer, Novartis, NanoString Technologies, and AstraZeneca; consulting/advisory board roles at Amgen, Roche, Daiichi Sankyo, Genomic Health, Merck Sharp & Dohme, Lilly, Novartis, Astra Zeneca, and Eisai; and travel/accommodation/expenses from Roche, Celgene, Daiichi Sankyo. M.R. reports honoraria (self) and advisory/consultancy fees from Roche, Novartis, Merck Sharp & Dohme, AstraZeneca, Seagen, Somatex and Lilly; and travel expenses from Novartis and Pfizer and Celgene.